晨光生物
(300138)
| 流通市值：47.46亿 | | | 总市值：56.63亿 |
| 流通股本：4.46亿 | | | 总股本：5.33亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,732,327,232.51 | 6,871,515,007.68 | 5,169,444,187.28 | 3,668,696,988.23 |
| 营业收入 | 1,732,327,232.51 | 6,871,515,007.68 | 5,169,444,187.28 | 3,668,696,988.23 |
| 二、营业总成本 | 1,687,056,795.93 | 6,450,813,191.25 | 4,800,484,167.22 | 3,406,936,968.59 |
| 营业成本 | 1,590,135,324.56 | 6,073,599,318.08 | 4,537,459,857.09 | 3,236,975,859.81 |
| 税金及附加 | 3,894,473.22 | 16,771,739.78 | 12,034,033.8 | 8,278,108.49 |
| 销售费用 | 13,676,490.25 | 61,075,598.21 | 45,904,689.02 | 29,581,132.84 |
| 管理费用 | 34,633,265.94 | 154,612,330.46 | 115,681,594.85 | 76,818,840 |
| 研发费用 | 23,149,384.73 | 97,400,025.19 | 61,110,369.6 | 38,399,859.82 |
| 财务费用 | 21,567,857.23 | 47,354,179.53 | 28,293,622.86 | 16,883,167.63 |
| 其中:利息费用 | 31,754,697.59 | 83,507,323.17 | 60,947,433.02 | 42,128,967.66 |
| 其中:利息收入 | 9,921,600.28 | 35,633,978.21 | 26,698,664.08 | 15,308,197.11 |
| 加:公允价值变动收益 | -38,867,464.25 | 5,363,332.98 | -2,650,493.03 | 6,583,420.53 |
| 加:投资收益 | 32,773,543.61 | 68,650,895.5 | 53,586,419.2 | 47,643,119.38 |
| 资产处置收益 | - | -632,753 | 189.31 | -1,551.18 |
| 资产减值损失(新) | -2,430,131.31 | 4,056,267.83 | 12,384,026.19 | 12,907,442.35 |
| 信用减值损失(新) | -154,726.49 | -1,126,405.44 | -334,600.91 | -541,519.32 |
| 其他收益 | 7,753,127.8 | 51,311,383.13 | 32,879,528.9 | 25,625,090.04 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 44,344,785.94 | 548,324,537.43 | 464,825,089.72 | 353,976,021.44 |
| 加:营业外收入 | 458,280.39 | 9,905,518.64 | 8,315,832.46 | 4,072,197.18 |
| 减:营业外支出 | 549,538.47 | 2,411,388.15 | 1,991,681.07 | 1,466,069.02 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 44,253,527.86 | 555,818,667.92 | 471,149,241.11 | 356,582,149.6 |
| 减:所得税费用 | 11,260,141.94 | 61,645,361.16 | 55,038,103.36 | 41,689,712.98 |
| 六、净利润 | 32,993,385.92 | 494,173,306.76 | 416,111,137.75 | 314,892,436.62 |
| 持续经营净利润 | 32,993,385.92 | 494,173,306.76 | 416,111,137.75 | 314,892,436.62 |
| 归属于母公司股东的净利润 | 38,591,936.61 | 479,722,222.22 | 398,355,550.46 | 298,654,394.22 |
| 少数股东损益 | -5,598,550.69 | 14,451,084.54 | 17,755,587.29 | 16,238,042.4 |
| (一)基本每股收益 | 0.07 | 0.9 | 0.75 | 0.56 |
| (二)稀释每股收益 | 0.07 | 0.9 | 0.75 | 0.56 |
| 八、其他综合收益 | 567,008.04 | 7,223,216.27 | 13,422,891.22 | 19,050,485.22 |
| 归属于母公司股东的其他综合收益 | 567,008.04 | 7,223,216.27 | 13,422,891.22 | 19,050,485.22 |
| 九、综合收益总额 | 33,560,393.96 | 501,396,523.03 | 429,534,028.97 | 333,942,921.84 |
| 归属于母公司股东的综合收益总额 | 39,158,944.65 | 486,945,438.49 | 411,778,441.68 | 317,704,879.44 |
| 归属于少数股东的综合收益总额 | -5,598,550.69 | 14,451,084.54 | 17,755,587.29 | 16,238,042.4 |
| 公告日期 | 2024-04-25 | 2024-04-18 | 2023-10-24 | 2023-08-14 |
| 审计意见(境内) | | 标准无保留意见 | | |